Dr. Michael Brundage is stepping down, to be succeeded by Dr. Winson Cheung. Wednesday, May 20, 2020 After 22 years in his position as QOL committee co-chair, Dr. Michael Brundage is stepping down, to be succeeded by Dr. Winson Cheung. Dr. Brundage has been engaged with the Clinical Trials Group since he was a Terry Fox Research Fellow with the Group in 1989 and 1990. During that time, he completed an MSc in Epidemiology (incidentally under my supervision), which included carrying out a thesis project on observer variation in the recording of adverse events that substantially influenced our thinking on the need for obtaining such information directly from patients. Dr. Brundage joined Dr. Andrea Bezjak as QOL co-chair in late 1998. Andrea had succeeded the original QOL chair, Dr. David Osoba, in 1997. Dr. Brundage, along with Dr. Bezjak and Dr. Jolie Ringash who succeeded Dr. Bezjak in 2006, presided over a remarkable expansion of the activities of the QOL committee within the Group, but also with respect to its international impact. Dr. Brundage will remain a member of the committee and will keep us connected to important initiatives in the US and in Europe. We are grateful for his many contributions to our programme. Dr. Cheung is a Medical Oncologist and a Professor of Medicine in the Department of Oncology at the University of Calgary. His primary research focus is in Health Services with broad interests in health economics, the use of administrative data and patient report outcomes. We look forward to the substantial contributions we are sure he will make to the evolution of our QOL program. Meanwhile, Dr. Ringash, having served as co-chair of the committee since 2006, would like to relinquish her role in the coming year. Anyone interested in taking on a leadership position in this important area of CCTG’s research should contact me or Dr. Dancey. Joe Pater, Senior Investigator for QOL committee
